UY29964A1 - Formas de cristal f,g,h,i, y k del mesilato de imatinib - Google Patents

Formas de cristal f,g,h,i, y k del mesilato de imatinib

Info

Publication number
UY29964A1
UY29964A1 UY29964A UY29964A UY29964A1 UY 29964 A1 UY29964 A1 UY 29964A1 UY 29964 A UY29964 A UY 29964A UY 29964 A UY29964 A UY 29964A UY 29964 A1 UY29964 A1 UY 29964A1
Authority
UY
Uruguay
Prior art keywords
crystal form
crystal forms
warm
methyl
preparation
Prior art date
Application number
UY29964A
Other languages
English (en)
Spanish (es)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY29964A1 publication Critical patent/UY29964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY29964A 2005-11-25 2006-11-23 Formas de cristal f,g,h,i, y k del mesilato de imatinib UY29964A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
US74001805P 2005-11-28 2005-11-28
US74001605P 2005-11-28 2005-11-28
US74001705P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
UY29964A1 true UY29964A1 (es) 2007-06-29

Family

ID=37847165

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29964A UY29964A1 (es) 2005-11-25 2006-11-23 Formas de cristal f,g,h,i, y k del mesilato de imatinib

Country Status (13)

Country Link
US (6) US7893076B2 (enExample)
EP (3) EP2578580A1 (enExample)
JP (2) JP5844508B2 (enExample)
KR (4) KR20130141712A (enExample)
CN (1) CN102351842B (enExample)
AU (2) AU2006316823A1 (enExample)
BR (1) BRPI0618993A2 (enExample)
CA (3) CA2824301C (enExample)
EC (1) ECSP088473A (enExample)
MY (1) MY146403A (enExample)
NO (1) NO20082684L (enExample)
UY (1) UY29964A1 (enExample)
WO (1) WO2007059963A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
AU2006316823A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
RU2365587C1 (ru) * 2008-02-22 2009-08-27 Закрытое Акционерное Общество "Фарм-Синтез" Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
EP2536707A1 (en) 2010-02-15 2012-12-26 Reliance Life Sciences Pvt., Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
WO2015081175A1 (en) * 2013-11-26 2015-06-04 Children's Medical Center Corporation Expandable stent valve
PL3539138T3 (pl) 2016-11-11 2021-12-13 Curium Us Llc Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
WO2004106326A1 (en) * 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
PL1720853T3 (pl) * 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
KR101246863B1 (ko) 2004-06-04 2013-03-25 바이오니취 라이프 사이언시즈 인코포레이티드 간 장애 및 바이러스성 감염의 치료를 위한 이매티닙의용도
TR200701870T1 (tr) 2004-09-02 2007-05-21 Cipla Limited İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
WO2006048890A1 (en) 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
JP2009506014A (ja) 2005-08-26 2009-02-12 ノバルティス アクチエンゲゼルシャフト イマチニブメシレートのデルタおよびイプシロン結晶形
AU2006316823A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
CN102351842A (zh) 2012-02-15
US8846706B2 (en) 2014-09-30
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
AU2006316823A1 (en) 2007-05-31
AU2011201286A1 (en) 2011-04-07
BRPI0618993A2 (pt) 2011-09-20
EP1960380A1 (en) 2008-08-27
JP2009517353A (ja) 2009-04-30
JP5844508B2 (ja) 2016-01-20
US8198289B2 (en) 2012-06-12
CN102351842B (zh) 2014-07-23
US20120015955A1 (en) 2012-01-19
US20110171301A1 (en) 2011-07-14
US20130224288A1 (en) 2013-08-29
CA2824307A1 (en) 2007-05-31
WO2007059963A1 (en) 2007-05-31
KR20130140909A (ko) 2013-12-24
CA2824301C (en) 2016-01-12
US20120226038A1 (en) 2012-09-06
JP2014074067A (ja) 2014-04-24
MY146403A (en) 2012-08-15
KR20080078804A (ko) 2008-08-28
US8592440B2 (en) 2013-11-26
EP2578580A1 (en) 2013-04-10
CA2824301A1 (en) 2007-05-31
KR20130137721A (ko) 2013-12-17
US20120015027A1 (en) 2012-01-19
CA2628330C (en) 2015-06-16
KR20130141712A (ko) 2013-12-26
CA2628330A1 (en) 2007-05-31
EP2546248A1 (en) 2013-01-16
US20080268040A1 (en) 2008-10-30
ECSP088473A (es) 2008-06-30
NO20082684L (no) 2008-08-15
CA2824307C (en) 2016-03-29
US8507515B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
ECSP088473A (es) FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
CO6382134A2 (es) Sales y formas de cristal del 2-metil-2-[4-(metil-2-oxo-8-quinolin-3-3il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]propionitrilo
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
PE20150998A1 (es) Inhibidores de histona demetilasas
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
MX348290B (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
GT200500307A (es) Compuestos quimicos
UY29633A1 (es) Derivados de oxindol
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112014011981B8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
CR9722A (es) Derivados de benzilpiperazina y su uso medico
AR114032A2 (es) 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112014009165A2 (pt) sal e uso médico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161212